Hologic Inc, Hologic announced that its subsidiary, Biotheranostics, received a positive coverage determination from Medicare for Its Breast Cancer Index genomic test. The Breast Cancer Index test is used to predict the likelihood of recurrence in early-stage, hormone receptor-positive breast cancer patients.
BD (Becton, Dickinson, and Company). BD announced the launch of the BO Intevia 1mL two-step disposable autoinjector, which is used for the subcutaneous injection of biological drugs. The device is designed to enhance patient experience and medication adherence by providing a reliable, easy-to-use, and customizable Infection experience. The BD Intevia autoinjector is part of the company's broader portfolio of products for drug delivery and administration.
Author Credits: Radhika Gupta, Shivam Bhutani
Report ID: 747
Published Date: Aug 02, 2023
Report Format: PDF, PPT
Frequently Asked Questions (FAQ)
The growing incidence of breast cancer and the expansion of healthcare spending are some of the major factors anticipated to drive the growth of the breast biopsy market.
The market is anticipated to attain a CAGR of ~6% over the forecast period, i.e., 2023 â€“ 2035.
The major players in the market are Danaher Corporation, BD (Becton, Dickinson, and Company), Cook Medical LLC, Argon Medical Devices, Inc., B. Braun Melsungen AG, C.R. Bard, Inc., and others.
The hospital segment is anticipated to garner the largest market size by the end of 2035 and display significant growth opportunities.
The market in Asia Pacific is projected to hold the largest market share by the end of 2035 and provide more business opportunities in the future.